Abstract: More than 50% of patients with erectile dysfunction (ED) showed erectile tissues pathological changes include corpus cavernous fibrosis, endothelial dysfunction, arterial and/or vein disorder, neuropathy and hormon disorder et al. Currently used on demanded treating ED therapies, include oral medication using PDE5i, intracavernosal injection (ICI) therapy, vacuum device et al., the clinical efficacies of reached to 70% with some kinks of adverse events, however, these therapies showed no effects on sever ED with sever pathological changes in erectile tissue. Penile prosthesis implantation (PPI) is the solution of choice in patients who have failed or present contraindication to the use of all conservative treatment for ED. We retrospectively evaluated the clinical outcome of PPI in Chinese patients with severe erectile dysfunction (SED) from July 2000 to December 2011, 224 patients, overall satisfaction with the PPI surgery was reported by 89.0% of men and 82.5% of partners, mechanical malfunction occurred in 4 cases (2.0%) and 3 cases were re-implanted new device, and 2 cases (1.0%) developed a mild curvature of the penis. Scrotal erosion with infection occurred in 1 case with diabetes mellitus (0.5%) and required complete removal of the implanted AMS 700 CXM. After 3 years no PPI device available in China, AMS 700CXR finally approved by China SDA recently, and the quality this device is improved very much compared to AMS700CXM, and the long-term mechanical reliability studies on AMS 700CXR noted that the clinical efficacy and device service of AMS 700CXR showed significantly better than that of AMS 700 CXM, which yields excellent results in terms of cosmetic and functional outcome and therefore has a significant impact on patients' satisfaction, sex life and overall quality of life. Overall, long term reliability has been significantly improved and complication rates are low in the hands of experienced surgeons.
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